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BACKGROUND
In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is 
less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.
METHODS
In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least 
12 years of age and who had mild, persistent asthma to receive mometasone (an inhaled 
glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo. The patients 
were categorized according to the sputum eosinophil level (<2% or ≥2%). The primary 
outcome was the response to mometasone as compared with placebo and to tiotropium 
as compared with placebo among patients with a low sputum eosinophil level who had 
a prespecified differential response to one of the trial agents. The response was deter-
mined according to a hierarchical composite outcome that incorporated treatment failure, 
asthma control days, and the forced expiratory volume in 1 second; a two-sided P value 
of less than 0.025 denoted statistical significance. A secondary outcome was a compari-
son of results in patients with a high sputum eosinophil level and those with a low level.
RESULTS
A total of 73% of the patients had a low eosinophil level; of these patients, 59% had a 
differential response to a trial agent. However, there was no significant difference in the 
response to mometasone or tiotropium, as compared with placebo. Among the patients 
with a low eosinophil level who had a differential treatment response, 57% (95% confi-
dence interval [CI], 48 to 66) had a better response to mometasone, and 43% (95% CI, 
34 to 52) had a better response to placebo (P = 0.14). In contrast 60% (95% CI, 51 to 68) 
had a better response to tiotropium, whereas 40% (95% CI, 32 to 49) had a better re-
sponse to placebo (P = 0.029). Among patients with a high eosinophil level, the response 
to mometasone was significantly better than the response to placebo (74% vs. 26%) but 
the response to tiotropium was not (57% vs. 43%).
CONCLUSIONS
The majority of patients with mild, persistent asthma had a low sputum eosinophil level 
and had no significant difference in their response to either mometasone or tiotropium 
as compared with placebo. These data provide equipoise for a clinically directive trial to 
compare an inhaled glucocorticoid with other treatments in patients with a low eosino-
phil level. (Funded by the National Heart, Lung, and Blood Institute; SIENA ClinicalTrials 
.gov number, NCT02066298.)
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Asthma is heterogeneous, and many patients do not have an acceptable re-sponse to currently available treatment, 
most of which targets eosinophilic inflammation. 
In previous studies, investigators found that ap-
proximately half of patients with asthma had a 
poor response to inhaled glucocorticoids1-3 and 
that eosinophilic airway inflammation was not 
ubiquitous in the patients.4-7 In contrast to pa-
tients who have a percentage of sputum eosino-
phils of 2% or more, in whom the forced expira-
tory volume in 1 second (FEV1) increases with 
the use of inhaled glucocorticoids, those with a 
low eosinophil level (<2%) may not have a re-
sponse to glucocorticoids.7 Thus, the two sub-
groups of eosinophil levels may represent two 
different phenotypes of asthma with different 
needs for therapy.8,9
Guidelines recommend the use of inhaled 
glucocorticoids in all patients with persistent 
asthma.10,11 Because in approximately 50% of 
patients, mild, persistent asthma may not be as-
sociated with sputum eosinophilia, it is impor-
tant to determine prospectively whether these 
patients benefit from inhaled glucocorticoids and, 
if not, to consider alternative treatments. Since 
the risk of monotherapy with long-acting beta-
agonists (LABAs)12 ruled out their use, we con-
sidered tiotropium, a long-acting muscarinic 
antagonist (LAMA), as a safe alternative in a 
controller medication.13-16 Thus, in the Steroids 
in Eosinophil Negative Asthma (SIENA) trial, we 
compared an inhaled glucocorticoid (mometa-
sone) and tiotropium with placebo in patients 
with mild, persistent asthma, according to the 
patients’ sputum eosinophil level at baseline.
Me thods
Patients
We enrolled patients who were at least 12 years 
of age and who had received a clinical diagnosis 
of asthma and met the guideline criteria of the 
National Asthma Education and Prevention Pro-
gram for step 2 asthma treatment.10,11 The asthma 
diagnosis was confirmed by either an increase of 
200 ml in the FEV1 (and representing an increase 
of ≥12%) after the administration of albuterol or 
a 20% reduction in FEV1 in response to a pro-
vocative concentration of inhaled methacholine 
(PC20) of 16 mg per milliliter or less. Patients 
were excluded if they had received an inhaled 
glucocorticoid within 3 weeks, an oral gluco-
corticoid within 6 weeks, or omalizumab within 
3 months; had a respiratory infection within 
4 weeks; had any cigarette use during the previ-
ous 12 months or a lifetime use of more than 
10 pack-years; had a history of life-threatening 
asthma; or had an FEV1 of less than 70% of the 
predicted value.
Trial Design
We conducted this randomized, double-blind, 
placebo-controlled crossover trial at 24 sites in the 
United States that are included in the AsthmaNet 
consortium of the National Heart, Lung, and 
Blood Institute (NHLBI). The protocol, modifi-
cations, and statistical analysis plan are avail-
able with the full text of this article at NEJM.org. 
Adult patients provided written informed con-
sent; for adolescents, parents or legal guardians 
provided written informed consent, and adoles-
cents provided assent.
The patients were enrolled in a 6-week, single-
blind placebo run-in period for characterization 
of their asthma, sputum eosinophilia, and asth-
ma control and to establish adherence of more 
than 75% to the trial agent and daily completion 
of an electronic diary (Fig. 1A). Spirometric mea-
Figure 1 (facing page). Trial Design and Randomization.
Panel A shows the trial design calling for the enrollment 
of patients who met the guideline criteria for step 2 
asthma treatment in a 6­week single­blind placebo run­
in period for characterization of asthma. Sputum induc­
tion (SI) was performed up to three times to guarantee 
the collection of two acceptable samples. At the end of 
the run­in period, patients who continued to meet the 
criteria for step 2 treatment and who met the adherence 
criteria for medication use and diary completion were 
stratified according to the sputum eosinophil (EOS) 
level (<2% or ≥2%) and were randomly assigned to 
 receive one of three blinded regimens in random se­
quence for 12 weeks each. Throughout the trial, patients 
used an electronic diary to record asthma symptoms, 
nighttime awakenings, and morning and evening peak 
expiratory flow. Inhaler use was tracked by device dose 
counters. Panel B shows the number of patients who 
enrolled in the trial, underwent randomization, and 
completed the trial. A sputum sample was deemed to be 
unacceptable if it contained more than 80% squamous 
cells, if there was an inadequate sputum volume, or if 
the patient was unable to continue the induction pro­
cedure for at least 4 minutes. After 74 patients were 
categorized as being in the high­eosinophil stratum, 
subsequent patients with a high eosinophil level did 
not undergo randomization.
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surements were performed and albuterol revers-
ibility was assessed at the first visit. If reversi-
bility was not shown, the patients returned for 
methacholine bronchoprovocation before the sec-
ond visit. Sputum induction was performed up 
to three times during the run-in period to obtain 
B Enrollment and Randomization
A Trial Design
295 Underwent randomization
564 Patients entered run-in period
269 Were excluded
44 Withdrew consent
84 Had unacceptable sputum sample
40 Had EOS ≥2% after stratum closed
24 Had asthma exacerbation or 2 treatment
failures
27 Were lost to follow-up
29 Were nonadherent
6 Had adverse event
15 Had other reasons
221 Were assigned to low-EOS stratum 74 Were assigned to high-EOS stratum
204 (92%) Completed period 1 71 (96%) Completed period 1
184 (83%) Completed period 2 67 (91%) Completed period 2
176 (80%) Completed period 3 65 (88%) Completed period 3
26 Withdrew consent
14 Were lost to follow-up
5 Had other reasons
9 Withdrew consent
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two acceptable samples for cell counts on the 
basis of a validated protocol.3,12,17,18
The patients were classified as having a high 
eosinophil level if eosinophils made up at least 
2% of at least one sputum sample. Patients with 
two sputum samples that contained less than 
2% of eosinophils were designated as having a 
low eosinophil level. We obtained samples of 
serum periostin, blood eosinophils, and exhaled 
nitric oxide each time sputum induction was per-
formed. The patients entered the double-blind 
crossover phase at the end of the run-in period 
if they continued to meet the criteria for step 2 
treatment, had provided two acceptable sputum 
samples, met the adherence criteria for medica-
tion use and diary completion, did not have two 
or more episodes of treatment failure or one 
asthma exacerbation (Sections 4.1 and 4.2 in the 
Supplementary Appendix, available at NEJM.org), 
and the severity of asthma had not escalated to 
meet the criteria for step 3 treatment.
Protocol Revision
We anticipated that approximately 50% of the 
recruited patients would have a low eosinophil 
level.7,8 However, after 112 patients had under-
gone randomization, we found that 76% of these 
patients who first enrolled in the trial had a low 
eosinophil level. Thus, we revised the order of 
our trial objectives to focus the primary outcome 
on a comparison between an inhaled glucocorti-
coid and placebo and between a LAMA and 
placebo among the patients with a low eosino-
phil level. Comparisons of treatments in the high-
eosinophil stratum and between the two eosino-
phil strata became secondary objectives and were 
included as an important positive control but not 
for outcome comparisons. This change in the 
priority of trial objectives occurred while all 
outcome data were masked and before the com-
pletion of enrollment and analysis of the trial 
results. The revision was approved by the steering 
committee, by the NHLBI, and by the NHLBI-
appointed data and safety monitoring board.19
Trial Regimens
We assigned patients in the two eosinophil 
strata to a three-treatment, crossover trial for a 
total of 36 weeks of randomized treatment. Dur-
ing each 12-week period, the patients received 
twice-daily mometasone (at a dose of 220 μg 
with the Asmanex Twisthaler or 200 μg with the 
Asmanex HFA [Merck]), once-daily tiotropium 
(at a dose of 5 μg with Spiriva Respimat [Boeh-
ringer Ingelheim]), or twice-daily placebo. (De-
tails regarding the assignment of the inhaler 
device are provided in Section 6.1 in the Supple-
mentary Appendix.) Trial-group assignments were 
masked by the use of matched masked inhalers 
that delivered placebo. To account for transition-
ing from one trial group to another, diary data 
from the initial 4 weeks of each 12-week treat-
ment period were omitted from the analysis. 
Treatment failure and asthma exacerbations that 
occurred during this 4-week transition period 
were counted as events assigned to the ongoing 
trial agent.
Evaluation Instruments
All the patients used an electronic diary (Spirotel, 
Medical International Research) to record symp-
toms, medication use, nighttime awakenings, 
and morning and evening peak expiratory flow. 
The patients were seen every 6 weeks and as-
sessed by phone at the 3-week point between 
visits. We used standard AsthmaNet procedures 
to assess asthma characteristics.20,21 In addition, 
we administered the Asthma Control Test (in 
which scores range from 5 [uncontrolled] to 25 
[well controlled], with a minimally important 
difference of 3)22 and the Asthma Bother Profile 
(in which scores range from 0 [minimum effect] 
to 75 [maximum effect])23 at every visit. During 
visits 3, 5, 7, and 9, we administered the Asthma 
Symptom Utility Index (which ranges from 0 
[worse symptoms] to 1 [fewer symptoms], with 
a minimally important difference of 0.09),24 the 
Asthma-Specific Work Productivity and Activities 
Impairment Questionnaire (with results expressed 
as an impairment percentage),25 and the Sinonasal 
Questionnaire (which evaluates the frequency of 
nasal symptoms on a scale from 0 [never] to 3 
[daily])26 (Table S3 in the Supplementary Appendix).
Safety Assessments
Safety criteria were defined to ensure that the 
patients whose asthma control worsened received 
additional treatment early, before the develop-
ment of an exacerbation. Treatment failure was 
defined and addressed as described previously 
(Section 4.1 in the Supplementary Appendix).27 
Patients who met the criteria for treatment fail-
ure received an open-label, high-dose inhaled 
glucocorticoid (mometasone at a dose of 440 μg 
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twice daily for 10 days) in addition to the double-
blind trial agent. When necessary, the treatment 
period was extended so that at least 3 weeks 
elapsed between treatment with a high-dose in-
haled glucocorticoid and crossover to the next 
trial period or trial completion. Patients who 
had two or more treatment failures or an asthma 
exacerbation during one treatment period were 
crossed over to the next treatment period or 
completed their final visit.
Outcome Measures
The primary outcome was the response to momet-
asone as compared with placebo and to tiotro-
pium as compared with placebo among patients 
with a low eosinophil level who had a prespeci-
fied differential response to a trial agent. The 
response was determined according to a hierar-
chical composite outcome of asthma control that 
incorporated treatment failure, annualized num-
ber of asthma control days (defined as the number 
of days without the rescue use of albuterol, the 
use of a concomitant asthma medication, symp-
toms, urgent care visits, or peak expiratory flow 
at <80% of the baseline value), and FEV1 on the 
basis of prespecified threshold criteria. We as-
sessed the differential response for the com-
parisons between both mometasone and tiotro-
pium with placebo.
The patients were defined as having a differ-
ential response if no treatment failures occurred 
in one period and at least one failure occurred in 
another trial period, if the number of annualized 
asthma control days was at least 31 days higher 
than that in another trial period, or if the FEV1 
at the end of the period was at least 5% higher 
than that in another trial period. If one trial 
agent (either of the active drugs or placebo) was 
better than the other with respect to the thresh-
old for treatment failure, we ignored the number 
of asthma control days and FEV1. If there was no 
difference for treatment failure, and the thresh-
old for the number of asthma control days was 
met, we ignored the FEV1. If there was no differ-
ence with respect to either treatment failure or 
the number of asthma control days, we consid-
ered the FEV1 in the analysis. A patient was 
considered to have no differential response with 
respect to a given comparison if none of the 
thresholds were met.
Although we used a combination of all three 
hierarchical measures as a composite primary 
outcome, each individual measure was consid-
ered separately as a secondary outcome. The 
secondary outcomes and prespecified exploratory 
outcomes are described in Sections 5.1 and 5.2 
in the Supplementary Appendix.
Trial Oversight
The trial was funded by the NHLBI and approved 
by the AsthmaNet steering committee, an NHLBI-
appointed protocol review committee, and a data 
and safety monitoring board. Mometasone and 
mometasone placebo were donated by Merck, 
tiotropium and tiotropium placebo by Boehringer 
Ingelheim, and albuterol by Teva. These compa-
nies did not play a role in the design of the trial, 
in the collection or interpretation of the data, or 
in the preparation of the manuscript. Each of the 
companies received a copy of the manuscript at 
the time that it was submitted for publication.
The authors were responsible for the trial 
design, data collection, data interpretation and 
analysis, manuscript preparation, and decision 
to submit the manuscript for publication. The 
authors vouch for the accuracy and completeness 
of the data, for the accuracy of the analyses, and 
for the fidelity of the trial to the protocol.
Statistical Analysis
The primary research questions were whether an 
inhaled glucocorticoid (mometasone) or a LAMA 
(tiotropium) was superior to placebo among pa-
tients with a low eosinophil level who had a 
differential response. We determined that a sam-
ple of 262 patients in this stratum would provide 
a power of 90% at a two-sided significance of 
0.025 (Bonferroni correction) to detect a differ-
ence in probabilities of 0.20 while allowing for a 
15% withdrawal rate and a 30% rate of no dif-
ferential response. With the approval of the data 
and safety monitoring board, we closed enroll-
ment at 221 patients in the low-eosinophil stra-
tum, which provided a power of just under 85%.19
To evaluate each null hypothesis, we applied 
two-sided, exact binomial tests at the 0.025 sig-
nificance level to data from patients who had a 
differential response, according to the hierarchi-
cal composite outcome. To assess potential ef-
fects of the trial period and seasonal factors, 
we performed a sensitivity analysis by applying 
logistic-regression models to data from patients 
who had a differential response, with covariates 
to adjust for differences between trial periods, 
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seasons of enrollment, and delivery device for 
mometasone (dry powder vs. metered-dose in-
haler) (see Section 6.1 in the Supplementary 
Appendix).
Prespecified secondary analyses with the pri-
mary hierarchical composite outcome included 
the same analysis performed with data from 
patients in the high-eosinophil stratum, a com-
parison between mometasone and tiotropium 
performed in the same manner as described for 
the comparison between placebo and mometa-
sone or tiotropium, and an exploratory subgroup 
analysis to evaluate the coprimary research 
hypotheses in adults only. We created receiver-
operating-characteristic (ROC) curves and esti-
mated the area under the curve (AUC) to deter-
mine the predictive value of other biomarkers for 
sputum eosinophilia or response to treatment. 
We used linear mixed-effects models to analyze 
secondary outcome measures for questionnaires 
and diary data for longitudinal data after adjust-
ment for baseline values, trial period, eosinophil 
stratum, and trial group within the eosinophil 
stratum, as well as a random effect for clini-
cal site.
All analyses were performed on the intention-
to-treat principle in which data were included for 
all the patients who had undergone randomiza-
tion. Patients with missing data were conserva-
tively assumed to have had a similar response to 
both mometasone and tiotropium, so these pa-
tients were imputed as not having had a differ-
ential response for the purpose of the intention-
to-treat analysis with the use of single imputation. 
A tipping-point analysis was performed to evalu-
ate the effect of various assumptions applied to 
patients with missing outcome data (see Section 
6.2 in the Supplementary Appendix).
R esult s
Patients
The trial was conducted from July 2014 through 
March 2018. Of the 564 patients who were en-
rolled in the run-in period, two acceptable spu-
tum samples were available for 366 patients. Of 
these samples, 268 (73%) were classified as hav-
ing a low eosinophil level and 98 (27%) as having 
a high eosinophil level. Of the remaining pa-
tients, 109 provided one acceptable sputum sam-
ple, and 89 provided no acceptable samples. Of 
the 366 patients with two acceptable sputum 
samples, 295 underwent randomization: 221 to 
the low-eosinophil subgroup and 74 to the high-
eosinophil subgroup (Table 1 and Fig. 1B, and Ta-
bles S1 and S2 in the Supplementary Appendix).
A total of 58 patients (20%) were between the 
ages of 12 and 18 years; of these patients, 40 
(69%) had a low eosinophil level. Among the 221 
patients with a low eosinophil level, those who 
completed at least two trial periods and provided 
data for each comparison in the primary analysis 
included 176 (80%) for the comparison between 
mometasone and placebo and 181 (82%) for the 
comparison between tiotropium and placebo, 
which permitted the assessment of a differential 
response. Among the 74 patients with a high 
eosinophil level, 67 (91%) completed the analysis 
periods for the comparison between mometa-
sone and placebo and 62 (84%) completed the 
periods for the comparison between tiotropium 
and placebo.
At the time of enrollment, all the patients had 
mild asthma (mean baseline FEV1 before bron-
chodilation, 90 to 93% of the predicted value). 
During the 12 months before enrollment, 23% 
had had at least one urgent care visit for asthma 
and 19% had received an oral glucocorticoid for 
asthma.
Adherence
There was no significant difference among the 
three trial groups in the rate of adherence to the 
blinded medications and to diary completion, as 
measured by the electronic devices used for this 
purpose. The rates did not vary according to 
eosinophil subgroup (Section 7.1 in the Supple-
mentary Appendix).
Differential Response to Trial Agents
A differential response for the comparison be-
tween mometasone and placebo was observed in 
130 of 221 patients (59%) with a low eosinophil 
level: 34% had better asthma control while receiv-
ing mometasone, 25% had better control while 
receiving placebo, 21% showed no between-group 
difference, and 20% with missing data were 
imputed as having no between-group difference. 
For the comparison between tiotropium and 
placebo, 36% had better control while receiving 
tiotropium, 24% had better control while receiving 
placebo, 22% showed no between-group differ-
ence, and 18% with missing data were imputed 
as having no between-group difference (Fig. 2A).
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Primary Analysis
Among the patients with a low eosinophil level 
who had a differential response, there was no 
significant difference between the percentage 
who had a better response to mometasone (57%; 
95% confidence interval [CI], 48 to 66) and 
those who had a better response to placebo 
(43%; 95% CI, 34 to 52; P = 0.14); there was also 
no significant difference in the percentage who 
had a better response to tiotropium (60%; 95% 
CI, 51 to 68) and those who had a better response 
to placebo (40%; 95% CI, 32 to 49; P = 0.029) 
(Fig. 2B). These conclusions did not change with 
sensitivity analyses that included adjustment for 
differences in the trial period, season of enroll-
ment, and mometasone delivery device. However, 
our conclusions were not robust to assumptions 
regarding missing data, since the results for the 
comparison between tiotropium and placebo 
would have been different under the missing-at-
random assumption. Although the results of the 
comparison between mometasone and placebo 
were the same under the missing-at-random as-
sumption, a tipping-point analysis showed that 
the results changed if we assumed that patients 
with missing data were twice as likely to have 
had a better response to mometasone than to 
placebo (Section 6.2 in the Supplementary Ap-
pendix).
Secondary Analyses
Among the patients with a high eosinophil level 
who had a differential response, 74% (95% CI, 
60 to 86) had a better response to mometasone 
Characteristic
Low Eosinophil Level 
(N = 221)
High Eosinophil Level 
(N = 74)
Demographic features
Age — yr 31.2±13.8 31.1±14.2
Male sex — no. (%) 76 (34) 35 (47)
Asthma history
Median age at diagnosis (IQR) — yr 8.0 (3.0–15.0) 7.0 (3.0–14.0)
Duration of asthma — yr 19.2±10.9 20.0±12.2
One or more asthma episodes requiring emergency care  
or unscheduled office visit in previous yr — no. (%)
52 (24) 17 (23)
One or more courses of systemic glucocorticoids in previous yr  
— no. (%)
41 (19) 14 (19)
Clinical and spirometric features
Body­mass index† 29.1±7.8 26.5±5.7
Predicted FEV1 — % 92.7±12.4 89.5±10.8
Ratio of FEV1 to FVC 0.77±0.08 0.75±0.08
Geometric mean PC20 (±CV) — mg/ml‡ 2.42±1.28 1.24±1.27
Bronchodilator response (4 puffs) — % change 9.6±7.1 12.7±8.5
Median fraction of exhaled nitric oxide (IQR) — ppb 21.5 (14.0–35.5) 55.5 (35.0–81.0)
Median blood eosinophil level (IQR) — % 2.6 (1.1–4.0) 4.8 (3.9–7.0)
Median periostin level (IQR) — ng/ml 51.7 (43.3–63.6) 56.3 (49.3–75.2)
Median score on Asthma Control Test (IQR)§ 21.0 (20.0–23.0) 21.0 (19.0–23.0)
Patients with eczema or atopic dermatitis — no. (%) 67 (30) 27 (36)
Patients with ≥1 positive allergen test — no./total no. (%) 172/216 (80) 70/72 (97)
*  Plus–minus values are means ±SD unless otherwise noted. CV denotes coefficient of variation, FEV1 forced expiratory 
volume in 1 second, FVC forced vital capacity, and IQR interquartile range.
†  The body­mass index is the weight in kilograms divided by the square of the height in meters.
‡  PC20 denotes the provocative concentration of inhaled methacholine that results in a 20% reduction in the FEV1.
§  The score on the Asthma Control Test ranges from 5 (uncontrolled) to 25 (well controlled), with a minimally important 
difference of 3.
Table 1. Characteristics of the Patients at Baseline.*
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and 26% (95% CI, 14 to 40) had a better re-
sponse to placebo; the corresponding better re-
sponses were 57% (95% CI, 41 to 72) to tiotro-
pium and 43% (95% CI, 28 to 59) to placebo 
(Fig. S1 in the Supplementary Appendix). The 
responses among the patients in the two eosino-
phil strata regarding the individual components 
of the hierarchical composite outcome are shown 
in Figures S2 and S3 in the Supplementary Ap-
pendix. In the two strata, the composite out-
come was driven by increases in the FEV1. 
Among the patients who had a differential re-
sponse and who had a better response to mometa-
sone than to tiotropium, there was no significant 
difference between the low-eosinophil stratum 
(48% vs. 52%) and the high-eosinophil stratum 
(55% vs. 45%) (Fig. S4 in the Supplementary 
Appendix).
 Exploratory Analyses in Adults
Among adults in the low-eosinophil stratum who 
had a differential response, 59% (95% CI, 49 to 
69) had a better response to mometasone and 
41% (95% CI, 31 to 51) had a better response to 
placebo; the corresponding percentages were 
62% (95% CI, 52 to 71) for tiotropium and 38% 
(95% CI, 29 to 48) for placebo. Among adults in 
the high-eosinophil stratum who had a differen-
tial response, 78% (95% CI, 62 to 90) had a bet-
ter response to mometasone and 22% (95% CI, 
10 to 38) had a better response to placebo; the 
corresponding percentages were 54% (95% CI, 
37 to 71) for tiotropium and 46% (95% CI, 29 to 
63) for placebo (Fig. S5 in the Supplementary 
Appendix).
We examined blood eosinophil levels and the 
fraction of exhaled nitric oxide as surrogates for 
the sputum eosinophil level by performing the 
two measurements whenever sputum samples 
were obtained. ROC curves showed that the 
blood eosinophil level was a “fair” predictor of a 
sputum eosinophil level of less than 2% and the 
fraction of exhaled nitric oxide was a “good” 
predictor,28 with AUCs of 0.77 and 0.80, respec-
tively. The blood eosinophil level and the frac-
tion of exhaled nitric oxide each predicted re-
sponse to mometasone (AUC, 0.63) but not to 
tiotropium (AUC, 0.48 and 0.54, respectively) 
(Figs. S6 through S8 in the Supplementary Ap-
pendix).
Figure 2. Pairwise Comparisons of Active Treatments and Placebo in the 
Low-Eosinophil Stratum.
In this trial, the primary outcome was the response to mometasone as 
compared with placebo and to tiotropium as compared with placebo 
among patients with a low sputum eosinophil level (<2%) who had a pre­
specified differential response to the trial agents. The response was deter­
mined according to a hierarchical composite outcome that incorporated 
treatment failure, asthma control days, and the forced expiratory volume in 
1 second. Panel A shows the prespecified differential response to treat­
ment with mometasone as compared with placebo and with tiotropium as 
compared with placebo. The patients were considered to have had a differ­
ential response if the response during at least one trial period was ranked 
better than the response during another trial period. In the comparison be­
tween mometasone and placebo, 34% of the patients had better asthma 
control while receiving mometasone, 25% had better control while receiv­
ing placebo, 21% showed no between­group difference, and 20% with 
missing data were imputed as having no between­group difference. In the 
comparison between tiotropium and placebo, 36% had better control while 
receiving tiotropium, 24% had better control while receiving placebo, 22% 
showed no between­group difference, and 18% with missing data were im­
puted as having no between­group difference. Panel B shows the results of 
a statistical comparison of the primary outcome among the patients who 
had a differential response to the trial agents, with a two­sided P value of 
less than 0.025 indicating statistical significance. There was no significant 
between­group difference in the percentage of patients who had a better 
response to mometasone than to placebo (57% vs. 43%, P = 0.14) or in the 
percentage who had a better response to tiotropium than to placebo (60% 
vs. 40%, P = 0.029). The I bars denote the 95% confidence interval.
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Other Measures of Control
In the patients with a high eosinophil level, 
scores on the Asthma Control Test and Asthma 
Symptom Utility Index were better among those 
who received mometasone than among those who 
received either tiotropium or placebo. The re-
sults for these and other secondary and explor-
atory outcomes — including findings on ques-
tionnaires, peak expiratory flow, and nocturnal 
awakenings — are listed in Table S3 in the 
Supplementary Appendix.
Adverse Events
There were few adverse events, asthma exacerba-
tions, or treatment failures among the patients. 
There was no significant difference in adverse 
events between the high-eosinophil stratum and 
the low-eosinophil stratum or between the two 
active treatment groups (Tables S4 and S5 in the 
Supplementary Appendix).
Discussion
Several key findings emerged from our trial of 
mometasone and tiotropium involving patients 
with mild, persistent asthma who were stratified 
according to sputum eosinophil level. Nearly three 
quarters of the patients who underwent screen-
ing (and who represented broad geographic and 
economic distribution within the United States) 
were identified as having a low eosinophil level, 
a percentage that is much greater than has been 
reported in this population previously.7
Although the patients had mild asthma, they 
had sufficient symptoms (on >2 days per week, 
>2 nights per month, or albuterol rescue on >2 days 
per week) to meet the criteria for step 2 treat-
ment (a daily inhaled glucocorticoid), according 
to the guidelines of the National Asthma Educa-
tion and Prevention Program. A substantial per-
centage of these patients were at risk for a loss 
of asthma control. Sputum eosinophilia has been 
shown to predict the response to glucocorticoid 
therapy,6,7,29 and patients with a low sputum 
eosinophil level or a low level of type 2 airway 
inflammation do not have a favorable response 
to glucocorticoids.7,9 This finding suggests that 
standard treatment with mometasone may not 
be effective in this population, and we examined 
that hypothesis prospectively in this trial.
The trial was designed to examine two pri-
mary comparisons among the patients in the 
low-eosinophil stratum: the differential response 
to mometasone and to tiotropium, as compared 
with placebo, for three measures of asthma con-
trol that incorporated treatment failure, asthma 
control days, and FEV1, with the use of pre-
specified threshold criteria. Nearly 60% of the 
patients in the low-eosinophil stratum had a 
differential response to one of the three trial 
agents, but the percentage who had a better re-
sponse to either active drug was not significantly 
greater than the percentage who had a better 
response to placebo. In contrast, in a secondary 
analysis in the high-eosinophil stratum, the re-
sponse to mometasone was clearly superior to 
the response to placebo.
We enrolled adolescents together with adults 
because the treatment guidelines include adoles-
cents in their recommendations. However, we 
prespecified separate exploratory analyses in 
the adult group and the adolescent group. When 
we reanalyzed the primary outcomes among the 
adults in the low-eosinophil stratum, a larger 
percentage had a better response to tiotropium 
than to placebo. Among the 58 patients in the 
adolescent group, 40 (69%) had a low eosinophil 
level. However, the numbers of adolescent patients 
in the two eosinophil strata are too small to allow 
for meaningful statistical comparisons.
The use of inhaled glucocorticoids is recom-
mended for nearly all patients with persistent 
asthma according to the belief that airway in-
flammation is ubiquitous in asthma and, if un-
treated, leads to airway remodeling.30,31 However, 
remodeling is far less common than once thought, 
and patients with a low level of type 2 airway 
inflammation do not have a favorable response to 
inhaled glucocorticoids. Our results extend these 
observations to a relatively large group of well-
characterized patients with mild asthma who 
have a persistent sputum eosinophil level of less 
than 2%. In our trial, sputum eosinophilia was 
assigned on the basis of two induced sputum 
samples obtained approximately 3 weeks apart, 
rather than after a single determination, to mini-
mize the potential of misclassification owing to 
variability over time.
Our results raise the question of whether 
treatment guidelines should be reevaluated for 
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patients with mild, persistent asthma for whom 
evidence of type 2 inflammation is lacking. 
Among such patients, adherence to prescribed 
regimens is often lacking because they tend to 
stop using inhaled glucocorticoids when they 
feel well, they have concern about potential ad-
verse effects, or they perceive that the treatment 
is ineffective. Although our data for patients in 
the low-eosinophil stratum do not support cur-
rent treatment recommendations, the appropriate 
controller treatment for these patients remains 
to be determined.
In our trial, 73% of the patients with mild, 
persistent asthma who underwent screening had 
a sputum eosinophil level of less than 2%; in 
67% of these patients, the response to placebo 
was either as good as or better than the re-
sponse to mometasone (Fig. S9 in the Supple-
mentary Appendix). The need for a change in 
treatment strategy is further highlighted by a 
growing body of literature suggesting that mild, 
persistent asthma can be managed safely with-
out the daily use of inhaled glucocorticoids and 
by data showing that patients with a low eosino-
phil level may not have a favorable response to 
inhaled glucocorticoids. Among patients with a 
low eosinophil level, the daily use of inhaled 
glucocorticoids may increase the risk of side ef-
fects and the costs of maintenance treatment, 
with minimal clinical benefit. Our findings pro-
vide clinical equipoise for a larger and longer 
study to compare inhaled glucocorticoids with 
other treatments for the large number of patients 
with mild or moderate asthma. Biomarkers that 
have been used to guide treatment mainly in 
severe or refractory asthma1-7,9,32,33 may provide 
valuable direction in future trials to identify 
patients who are most likely to have a response 
to inhaled glucocorticoids or to an alternative 
therapy.
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